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UM RESEARCHER RECEIVES GRANT FOR AIDS RESEARCH 
MISSOULA-
In support of groundbreaking research on a vaccine against HIV, the privately-funded 
American Foundation for AIDS Research (AmFAR) has awarded University of Montana 
virologist Jack H. Nunberg a second grant for 5142,000.
With another recent grant of $192,000 from the Elizabeth Glaser Pediatric AIDS 
Foundation, the total research funding for Nunberg’s lab has risen to more than $2 million for his 
novel approach to creating a way to protect people from AIDS.
Nunberg’s experimental vaccine involves capturing HIV protein in the midst of binding 
and fusion with cell-surface receptors. When genetically engineered mice were inoculated with 
this “fusion-competent” cell complex, they produced antibodies that were able to prevent HIV 
from infecting other cells in culture. This is the first vaccine to prove capable of inducing high 
levels of antibody activity against virtually all HIV subtypes in the world.
Nunberg and colleague Dan R. Littman of New York University Medical Center reported 
the results of their experiments last January in the journal Science.
Building on these successful early steps, Nunberg will use his new AmFAR grant to 
continue work with colleagues at Therion Biologies Corp. in Cambridge, Mass., on a vaccine
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delivery system (using recombinant poxvirus) that can be used safely in human trials. 
Experiments also are moving forward testing the vaccine in Rhesus monkeys, which, unlike 
current mouse models, can be infected directly with a related virus.
We are very grateful to AmFAR for their early and continuing support of our work on a 
vaccine, Nunberg said. “The private foundations play an important role in funding the early 
development of new ideas in the search for an AIDS vaccine.”
According to AmFAR, an estimated six million people worldwide were newly infected 
with HIV last year, spurring the search for a safe and effective AIDS vaccine. The foundation 
this year awarded nine grants totaling $953,031 in support of AIDS vaccine research and another 
10 grants totaling 5750,000 for studies on restoring the normal functioning of immune systems 
damaged by HIV. The awards were made on the eve of AIDS Vaccine Awareness Day, the 
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